Arthramid is a patented 2.5% injectable polyacrylamide hydrogel (iPAAG). Administered through intra-articular joint injection, it is integrated into the synovium of the joint, improving function and resolving lameness.
Arthramid goes beyond conventional therapies to safely and sustainably manage osteoarthritis.
- Increased load transfer capacity through the joint capsule
- Reduced effusion and decreased stiffness
- Over 80% of patients remain lame-free after one injection
Frequently Asked Questions
How long does Arthramid last?
Clinical and field data demonstrate improvement lasting 12–24 months, with some horses remaining sound for over 3 years. Duration depends on workload—performance horses may need re-treatment as per veterinary discretion.
Which horses and cases are suitable?
Arthramid is used safely in young and senior horses. Effective for OA, synovitis, meniscal injury, and tendon sheath inflammation. Not indicated for non-synovial joints (e.g., sacroiliac) or cases with active infection, cartilage fragments, or fracture.
What about older or metabolic horses?
Safe for senior or laminitic horses as Arthramid remains within the joint and reduces the need for systemic medications that affect the liver, kidneys, or GI tract.
Can young or preventative cases be treated?
Yes. Arthramid may be administered during early training in high-risk horses (e.g., racehorses or aged event horses) with diagnosed OA or synovitis as a measure to support joint health. Please see regulatory directives for further information regarding withdrawal times.
What is the recommended dosing strategy?
Supplied in prefilled 1 mL syringes. Dose typically 1–3 mL depending on joint volume, disease severity, and chronicity. If improvement is partial by 6 weeks, a top-up dose may be given.
What determines response time?
Early reduction in inflammation may appear in 1–2 weeks. Maximum integration and biomechanical support occur over 4–6 weeks. 7. What are the recommended rehabilitation guidelines following an Arthramid injection?
How should post-injection management be handled?
- 48 hours rest, ice every few hours if needed
- NSAIDs for 3–5 days
- Light turnout or hand-walking after 2–3 days
- Avoid intense exercise or competition for 3–4 weeks
How should owners be guided to ensure success?
Set clear expectations. Emphasize the need for rest and gradual return to work to maximize long-term outcomes. Encourage follow-up veterinary evaluations.
What if there is limited or no effect?
Consider diagnosis accuracy, joint localization, post-injection workload, or disease severity. Reactive joints or those with exposed bone may require stabilization or other alternatives prior to Arthramid.
What are the safety findings?
Used in tens of thousands of horses globally. Adverse events are rare and limited to mild transient swelling or effusion. Long-term studies confirm no systemic or neuro toxic effect, even after repeated treatments.
Is repeat or multiple treatment safe?
Yes. Horses have received multiple injections over years with no negative effects. The hydrogel volume is minimal and biocompatible.
Can it be combined with other treatments?
Compatible with NSAIDs, PSGAG’s, PPS, and other joint supplements. Corticosteroids should be spaced 2 weeks before or after injection to avoid altering the integration process.
What procedures should be avoided near treatment time?
Avoid concurrent intra-articular corticosteroids, aggressive laser, or shockwave therapy over the injection site for 2-4 weeks.
What differentiates Arthramid® from HA, PRP, or corticosteroids?
Arthramid is a 2.5% polyacrylamide hydrogel that integrates with the synovial membrane, forming a permanent viscoelastic scaffold. It reduces inflammation and restores joint biomechanics rather than simply masking pain.
In which joints or conditions is a flare more likely?
Coffin joints or reactive joints with subchondral bone exposure have higher risk of transient soreness post-injection. In these cases, pre-treatment with corticosteroids may be beneficial.
What are some advanced or novel applications?
Emerging evidence supports use in tendon sheaths, meniscal tears, navicular bursa, and even cervical articular facets. Outcomes depend on proper case selection and rest protocols.
How can clinicians maximize successful outcomes?
- Localize pain precisely via diagnostic blocks
- Select joints with active synovitis
- Ensure rest and staged rehabilitation
- Educate owners on realistic timelines for recovery